Skip to search formSkip to main contentSkip to account menu

remacemide

Known as: 2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

AcetamidesAnticonvulsantsNeuroprotective Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study
Review
2003
Review
2003
Remacemide--a novel potential antiepileptic drug.
Epilepsy belongs to common diseases of the brain. It affects approximately 1% of the population. The aim of epilepsy therapy is… 
Review
2002
Review
2002
Huntington's disease: the mystery unfolds?
Highly Cited
2001
Highly Cited
2001
A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke
2001
2001
Neuroprotective Effects of Lamotrigine and Remacemide on Excitotoxicity Induced by Glutamate Agonists in Isolated Chick Retina
The possible neuroprotective effects of two recently developed antiepileptic compounds, lamotrigine (LTG) and remacemide (REMA… 
Review
2000
Review
2000
Remacemide: current status and clinical applications
Remacemide (RMC) is a non-competitive, low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist that does not cause the… 
Review
2000
Review
2000
Clinical pharmacology of new antiepileptic drugs.
Advances in neurobiology, molecular biology, and pharmaceutical science have led to the development of a number of new… 
Highly Cited
1996
Highly Cited
1996
A controlled trial of remacemide hydrochloride in Huntington's disease
We conducted a randomized, double‐blind, placebo‐controlled tolerability study of a N‐methyl‐D‐aspartate (NMDA) glutamate… 
1996
1996
Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites
Summary: Purpose: We wished to determine mutual interaction of two drugs with active metabolism: remacemide, hydrochloride and… 
1992
1992
Classification of compounds for prevention of NMDLA-induced seizures/mortality, or maximal electroshock and pentylenetetrazol seizures in mice and antagonism of MK801 binding in vitro.
Intravenous injection of N-methyl-D,L-aspartic acid (NMDLA) into mice produces characteristic convulsions followed by death. The… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)